$BLLN

Johnson Nancy JoAnn sold $1.4M of BLLN

Johnson Nancy JoAnn (See Remarks) sold 14,000 shares of BillionToOne, Inc. (BLLN) at an average of $100.18 ($99.09–$102.34, $1.40M total) across 7 trades over 2026-06-08 to 2026-06-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Johnson Nancy JoAnn
Published Jun 11, 2026, 12:36 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 11, 2026, 1:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
medium confidence
Mentioned
$BLLN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider selling size, timing, and whether it was pre-arranged; it does not include operational or financial performance updates.

02

Market read

A $1.40M officer sale is a modest sentiment input, but the 10b5-1 structure limits interpretive value versus discretionary selling.

03

What to watch

Traders may overreact to insider sales; the key is whether there are concurrent news catalysts (earnings, trial updates, financing) not present in this filing.

Relevance 5/10Novelty 6/10Timing: Filed 2026-06-10; transaction dates 2026-06-08 to 2026-06-09

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for BillionToOne, Inc.

Company-level read

Ticker impact

$BLLNNeutralMedium confidence
Context

Officer Nancy JoAnn Johnson sold $1.40M of BillionToOne shares via an open-market sale under a pre-arranged 10b5-1 plan.

Expected impact

Near-term price reaction, if any, is likely limited; watch for follow-through in volume rather than a directional catalyst.

Evidence & confidence

The filing is a routine insider transaction and explicitly states a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

No sector-level implications; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish fundamentals.

Key entities

  • BillionToOne, Inc.

    Company whose officer executed open-market sales disclosed on Form 4.

  • Nancy JoAnn Johnson

    Officer who sold 14,000 shares (weighted avg ~$100.18) under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BLLNLow

BillionToOne's Northstar Response Shows High Concordance In Advanced Cancer Study

BillionToOne (BLLN) published a study showing its Northstar Response liquid biopsy assay had high concordance with a commercial ctDNA assay in advanced cancer patients. The study of 61 patients found 94% agreement in tumor burden change direction, with Northstar Response aligning with clinical ground truth in discordant cases. The assay detects disease progression even when tumors evolve post-biopsy. BLLN shares closed at $22.71, down 0.79%.

$BLLNMedAI 8/10

BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

BillionToOne (BLLN) announced a peer-reviewed study showing its Northstar Response® liquid biopsy assay performed on par or better than a tumor-informed assay in tracking cancer treatment. The study, published in The Journal of Liquid Biopsy, evaluated 169 samples from 61 patients, finding close alignment in results (R² = 0.97) and agreement in 94% of cases. Northstar Response detected disease progression in cases where the tumor-informed assay did not, highlighting its tumor-agnostic benefits.

$BLLNMedAI 8/10

BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move - BillionToOne (NASDAQ:BLLN)

BillionToOne (NASDAQ:BLLN) shares fell 28.12% in after-hours after reporting Q2 results. For the quarter ended June 30, 2026, revenue rose to $109.4M from $66.6M, net income was $8.1M ($0.15/share), and gross margin improved to 70%. The company kept 2026 revenue guidance of $450M to $465M and plans Unity Fetal Risk Screen (Aug. 17) and Northstar Origin (Sept. 1) launches.

$BLLNMed

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

BillionToOne, Inc. (BLLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance MENLO PARK, CA, August 5, 2026 - BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to al

$BLLNMedAI 8/10

Billiontoone (BLLN) – Research Analysts’ Recent Ratings Updates

BillionToOne (NASDAQ: BLLN) saw multiple analyst rating and target changes. Weiss Ratings upgraded BLLN to “sell (d+)” (from “sell (d)”) on 5/15 and reaffirmed “sell (d)” on 5/1. Guggenheim raised its target to $120 (from $100) and kept a “buy” on 5/13. JPMorgan lifted its target to $125 and maintained “overweight” on 5/7. BTIG cut its target to $130 (from $140) while keeping “buy” on 5/7.